4.5 Article

Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts

期刊

OSTEOPOROSIS INTERNATIONAL
卷 22, 期 6, 页码 1873-1883

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-010-1445-5

关键词

Bone mineral density; Canada; CAROC; Fracture risk prediction; FRAX; Osteoporosis

资金

  1. Manitoba Health [2007/2008-49]
  2. Amgen
  3. Merck Frosst
  4. sanofi-Aventis
  5. Procter Gamble
  6. Novartis
  7. AstraZeneca
  8. Pfizer
  9. Bayer
  10. Lilly
  11. Roche
  12. Servier
  13. Hologic
  14. Canadian Institutes of Health Research (CIHR)
  15. Merck Frosst Canada Ltd.
  16. Eli Lilly Canada Inc.
  17. Novartis Pharmaceuticals Inc.

向作者/读者索取更多资源

A procedure for creating a simplified version of fracture risk assessment tool (FRAXA (R)) is described. Calibration, fracture prediction, and concordance were compared with the full FRAX tool using two large, complementary Canadian datasets. The Canadian Association of Radiologists and Osteoporosis Canada (CAROC) system for fracture risk assessment is based upon sex, age, bone mineral density (BMD), prior fragility fracture, and glucocorticoid use. CAROC does not require computer or web access, and categorizes 10-year major osteoporotic fracture risk as low (< 10%), moderate (10-20%), or high (> 20%). Basal CAROC fracture risk tables (by age, sex, and femoral neck BMD) were constructed from Canadian FRAX probabilities for major osteoporotic fractures (adjusted for prevalent clinical risk factors). We assessed categorization and fracture prediction with the updated CAROC system in the CaMos and Manitoba BMD cohorts. The new CAROC system demonstrated high concordance with the Canadian FRAX tool for risk category in both the CaMos and Manitoba cohorts (89% and 88%). Ten-year fracture outcomes in CaMos and Manitoba BMD cohorts showed good discrimination and calibration for both CAROC (6.1-6.5% in low-risk, 13.5-14.6% in moderate-risk, and 22.3-29.1% in high-risk individuals) and FRAX (6.1-6.6% in low-risk, 14.4-16.1% in moderate-risk, and 23.4-31.0% in high-risk individuals). Reclassification from the CAROC risk category to a different risk category under FRAX occurred in < 5% for low-risk, 20-24% for moderate-risk, and 27-30% for high-risk individuals. Reclassified individuals had 10-year fracture outcomes that were still within or close to the original nominal-risk range.. The new CAROC system is well calibrated to the Canadian population and shows a high degree of concordance with the Canadian FRAX tool. The CAROC system provides s a simple alternative when it is not feasible to use the full Canadian FRAX tool.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据